Table 3. Association between EF one year before the interview and PCa according to ISUP and stage in CAPLIFE study.

EF (ejaculations/mo)		Model	Model 2	Model 3
ISUP 1–2
	>4	Reference
	4	1.45 (0.92–2.30)	1.46 (0.92–2.33)	1.63 (0.99–2.68)
	0–3	1.89 (1.26–2.83)	1.96 (1.30–2.96)	2.29 (1.47–3.57)
	p-trend	0.002	0.001	0.001
ISUP 3–5
	>4	Reference
	4	1.47 (0.67–3.26)	1.53 (0.68–3.43)	1.58 (0.68–3.65)
	0–3	2.53 (1.28–5.00)	2.46 (1.24–4.91)	2.76 (1.34–5.67)
	p-trend	0.004	0.006	0.003
Localized PCa
	>4	Reference
	4	1.42 (0.91–2.21)	1.43 (0.92–2.24)	1.59 (0.99–2.57)
	0–3	1.78 (1.21–2.63)	1.83 (1.23–2.71)	2.17 (1.42–3.33)
	p-trend	0.004	0.003	0.001
Locally advanced-metastatic PCa
	>4	Reference
	4	2.03 (0.57–7.24)	2.04 (0.57–7.37)	1.92 (0.52–7.06)
	0–3	5.61 (1.89–16.65)	5.21 (1.74–15.62)	4.70 (1.55–14.29)
	p-trend	0.001	0.001	0.002

Values are presented as adjusted odds ratio (95% confidence interval).

EF: ejaculation frequency, ISUP: International Society of Urological Pathology, PCa: prostate cancer.

Model 1: adjusted for age, educational level, and first-degree family history of PCa.

Model 2: adjusted for age, educational level, first-degree family history of PCa, height, sedentary behavior, diabetes mellitus, and vasectomy.

Model 3: adjusted for age, educational level, first-degree family history of PCa, height, sedentary behavior, diabetes mellitus, vasectomy, energy intake and alcohol consumption.